Critic of Sarepta's eteplirsen leaves FDA


A critic of Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) eteplirsen who lead the clinical review team of the Duchenne muscular dystrophy drug for the Food and Drug Administration has left the agency raising expectations that the new drug application for eteplirsen may finally be approved. Shares of the biopharmaceutical leaped $6.85 to close at $32.45.

About this Entry

This page contains a single entry by published on September 14, 2016 3:49 PM.

Allergan buys Vitae Pharmaceuticals was the previous entry in this blog.

SunPower extends losses is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12